Institute of Pathology

Intracranial hemorrhage in COVID-19 patients during extracorporeal membrane oxygenation for acute respiratory failure: a nationwide register study report (2022) von Stillfried S, Bülow RD, Röhrig R, Meybohm P, Boor P, Böcker J, Schmidt J, et al. Journal article Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells (2022) Shaikh H, Pezoldt J, Mokhtari Z, Vargas JG, Le DD, Mosca JP, Viera EA, et al. Journal article Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis (2022) Biedermann A, Mangelberger-Eberl D, Mougiakakos D, Büttner-Herold M, Flamann C, Kellner C, Altmeyer S, et al. Conference contribution Harnessing the Expression of TNFR2 on Tregs to Prevent Agvhd (2022) Vargas JG, Kanzler C, Scheller L, Kreckel J, Shaikh H, Lang I, Medler J, et al. Conference contribution Paraproteinemia and renal involvement (2022) Rupprecht H, Amann KU Journal article WHO 2022 classification of penile and scrotal cancers: updates and evolution (2022) Menon S, Moch H, Berney DM, Cree IA, Srigley JR, Tsuzuki T, Comperat E, et al. Journal article Low dietary fiber intake links development of obesity and lupus pathogenesis (2022) Schaefer AL, Eichhorst A, Hentze C, Kraemer AN, Amend A, Sprenger DTL, Fluhr C, et al. Conference contribution Early CRP kinetics predict long-term treatment success and favorable outcomes of anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma (2022) Klümper N, Sikic D, Saal J, Buettner T, Jarczyk J, Zeuschner P, Weinke M, et al. Conference contribution Updated analysis of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma with induction chemoimmunotherapy followed by radioimmunotherapy (2022) Hecht M, Eckstein M, Kallies A, von der Grün J, Illmer T, Klautke G, Laban S, et al. Conference contribution, Abstract of a poster A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (Everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study of the IAG-N) (2022) Hilser T, Gruenwald V, Bergmann L, Goebell P, Strauss A, Meiler J, Hartmann A, et al. Conference contribution